Introduction {#s1}
============

The role of the proteohormone ghrelin in the pathophysiology of depression is currently discussed. While ghrelin is secreted mainly at the fundus of the stomach, only small amounts are produced in the central nervous system. Ghrelin is able to cross the blood brain barrier and stimulates appetite and food intake by binding to its receptor (GHS-R1a) in the hypothalamus. GHS-R1a is expressed in numerous neuronal populations, and therefore the physiological role of ghrelin might include learning, memory, anxiety, depression, and neuroprotection ([@CIT0006]). A recent observation showed that plasma acylated ghrelin is associated with neural abnormalities in the ventral tegmental area, thereby modulating the reward system, which has been implicated in the pathophysiology of depression. Ghrelin modulates monoamine neurotransmission and the HPA axis, which both play an important role in the pathophysiology of depression. Furthermore, a polymorphism on ghrelin's encoding gene was described to be associated with depression ([@CIT0021]). An increase in ghrelin levels occurs not only in states of anergia but also follows acute and chronic stress. In summary, ghrelin signalling could play an important role in the pathophysiology of major depressive disorder (MDD), which still needs to be clarified.

Meta-analytical data show lithium augmentation (LA) of antidepressants as an effective strategy in MDD. The mechanisms underlying therapeutic efficacy of LA are still poorly understood, and individual response to LA cannot yet be predicted ([@CIT0003]). To the best of our knowledge, the course of ghrelin serum levels during lithium treatment and the association of treatment response with the course of ghrelin serum levels in the treatment of depression have not yet been investigated.

The purpose of this study was to investigate the association of treatment response with the course of ghrelin levels during LA by measuring ghrelin before and during LA in patients with MDD in a prospective cohort study.

We hypothesized that ghrelin is influenced by LA and that there is a different effect of LA in responders and nonresponders on ghrelin levels.

Methods {#s2}
=======

The study population was a subsample of a prospective cohort study investigating treatment response and side effect burden of LA in MDD. In this subsample, data on serum levels of ghrelin (baseline and study endpoint) were available in 85 patients (71 in- and 14 outpatients). The inclusion criteria were: MDD (according to DSM-IV cirteria) ([@CIT0001]), age older than 18 years, indication for an antidepressant pharmacotherapy, insufficient response to an adequate antidepressant pretreatment and clinical indication for lithium augmentation, a Hamilton Depression Rating Scale (HDRS-17; [@CIT0010]) score ≥12, and written informed consent. The respective diagnosis was confirmed using the Mini-International Neuropsychiatric Interview ([@CIT0028]). Patients were recruited between December 2008 and December 2012 in 12 psychiatric departments of the Berlin Research Network on Depression. The local ethics committee approved the study, and written informed consent was obtained from all subjects.

Ghrelin serum concentrations (nonfasting) were first measured in medicated patients before LA (baseline) and then after 4 weeks of co-medication with lithium (endpoint). Severity of depression (measured with HDRS-17) and body mass index (BMI, kg/m^2^) were measured on both occasions. Clinical response was defined as a HDRS-17 decrease of 50% or more. All patients received individual doses of lithium carbonate adapted to their individual lithium serum levels.

Endogenous ghrelin levels were measured in the rethawed serum samples using RayBio Ghrelin Enzyme Immunoassay (EIA) Kit, an in vitro quantitative assay based on the principle of competitive enzyme immunoassay. The detection range was 0.1 to 1.000 ng/mL, the intra-assay CV was \<10%, and the inter-assay CV was \<15%, according to the manufacturer's specifications ([@CIT0024]).

We used a linear mixed model for statistical analysis to investigate the effect of LA (time) as an explanatory factor for change in ghrelin levels. The differential effect of response to LA on change in ghrelin levels is represented by a response\*time interaction term. Linear mixed-effects models have the advantage of allowing the investigation of variability between patients (heterogeneity) and simultaneously adjusting for the within-subject correlation. In the present analysis, random effects were permitted for the intercepts. We entered time, gender, BMI, appetite, response, and response\*time interaction as fixed effects into the model. To control for the effect of appetite on ghrelin levels, we used the HRDS-17 item "12. Somatic symptoms (gastrointestinal)". Model regression coefficients are reported together with their 95% CI. We used SAS software, version 9.4. to perform the linear mixed model analysis and SPSS (version 21) for descriptive statistics, paired sample *t* test, and repeated-measures ANOVA-rm ([Table 1](#T1){ref-type="table"}). Significance level was set at .05 in all analyses.

###### 

Clinical Data and Results

                                             n (%)                                         Responder                 Nonresponder                     *P* Value\*
  ------------------------------------------ ----------- --------------------------------- ------------------------- -------------------------------- ---------------------
  Patients                                   85 (100)                                                                                                 
  Female                                     53 (62.4)                                     18 (52.9)                 35 (68.6)                        
  Male                                       32 (37.6)                                     16 (47.1)                 16 (31.4)                        \>.1
  Response                                   34 (40.0)                                                                                                
  Nonresponse                                51 (60.0)                                                                                                
  Psychotropic comedication                                                                                                                           
   Antidepressants                                                                                                                                    
   SSRI                                      47 (55.3)                                     16 (47.1)                 31 (60.8)                        \>.1
   SNRI                                      21 (24.7)                                     12 (35.3)                 9 (17.6)                         .65
   TCA                                       9 (10.6)                                      4 (11.8)                  5 (9.8)                          \>.1
   NDRI                                      4 (4.7)                                       0 (0.0)                   4 (7.8)                          .94
   Valdoxan                                  1 (1.2)                                       0 (0.0)                   1 (1.9)                          \>.1
   NaSSA                                     12 (14.1)                                     5 (14.7)                  7 (13.7)                         \>.1
   MAO-I                                     2 (2.4)                                       1 (2.9)                   1 (1.9)                          \>.1
  Atypical antipsychotics                    22 (25.9)                                     9 (26.5)                  13 (25.5)                        \>.1
  Antiepileptic drugs                        8 (9.4)                                       2 (5.9)                   6 (11.8)                         \>.1
  Benzodiazepines                            19 (22.4)                                     10 (29.4)                 9 (17.6)                         \>.1
  Low-potency antipsychotics                 4 (4.7)                                       0 (0.0)                   4 (7.8)                          .94
                                                         **Mean (SD**)                     **Responder mean (SD**)   **Nonresponder mean (SD**)       ***P* Value\*\***
  Age                                        85 (100)    48.31 ± 15.27                     50.00 ± 15.56             47.18 ± 15.12                    \>.1
  Lithium serum level (mmol/L) last visit    77 (90.6)   0.713 ± 0.152                     0.704 ± 0.146             0.719 ± 0.157                    \>.1
  HRDS-17 score baseline                     85 (100)    21.32 ± 5.03                      19.73 ± 4.94              22.35 ± 4.85                     \>.1
  HDRS-17 score last visit                   85 (100)    12.84 ± 7.59                      5.79 ± 2.95               17.53 ± 5.91                     \<.01
  BMI baseline                               84 (98.8)   25.54 ± 5.74                      26.27 ± 6.26              26.64 ± 6.14                     \>.1
  BMI last visit                             85 (100)    26.00 ± 5.69                      25.15 ± 5.44              25.58 ± 5.39                     \>.1
  Ghrelin serum level (ng/mL) baseline       84 (98.8)   5.71 ± 6.20                       6.50 ± 5.44               5.46 ± 4.90                      \>.1
  Ghrelin serum level (ng/mL) last visit     85 (100)    6.42 ± 6.99                       5.12 ± 6.71               7.05 ± 8.07                      \<.05
                                                         **Before lithium augmentation**                             **After lithium augmentation**   ***P* Value\*\*\***
  Ghrelin serum level (ng/mL)                84 (98.8)   5.71 ± 6.20                       85 (100)                  6.42 ± 6.99                      \<.05
  Ghrelin serum level (ng/mL) responder      36 (42.9)   6.50 ± 5.44                       36 (42.4)                 5.46 ± 4.90                      \>.1
  Ghrelin serum level (ng/mL) nonresponder   48 (57.1)   5.12 ± 6.71                       49 (57.6)                 7.05 ± 8.07                      \<.05
  HRDS-17 score                              85 (100)    21.32 ± 5.03                      85 (100)                  12.84 ± 7.59                     \<.05
  BMI                                        84 (98.8)   25.54 ± 5.74                      85 (100)                  26.00 ± 5.69                     \<.05^+^
  BMI responder                              34 (40.4)   26.27 ± 6.26                      34 (40.0)                 26.64 ± 6.14                     .052
  BMI nonresponder                           50 (59.5)   25.15 ± 5.44                      51 (60.0)                 25.58 ± 5.39                     \<.05

Abbreviations: BMI, body mass index; HDRS-17, Hamilton Depression Rating Scale; MAO-I, mono amine oxidase inhibitor (tranylcypromine); NaSSA, noradrenergic and specifically serotonergic antidepressant (mirtazapine); NDRI, norepinephrine and dopamine reuptake inhibitor (bupropione); reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

\*Result of Chi-square test; \*\*results of independent *t* test; all parameters were normally distributed;

\*\*\*results of paired sample *t* test; all parameters were normally distributed; the comparison of ghrelin and BMI before and after lithium augmentation (LA) was conducted with 84 patients, whereas mean and SD for the observation after LA are displayed for 85 patients in this table to present all data that were used for linear mixed model analysis.

+No significant effect of response on the course of BMI during LA was found in an ANOVA-rm (*P*\>.05).

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} provides information on measured ghrelin levels and clinical data as well as a basic statistical analysis of group characteristics (responders vs nonresponders) and the data that was used for linear mixed model analysis. In the following text and in [Figure 1](#F1){ref-type="fig"}, we present estimated values of ghrelin levels as a result of the linear mixed model analysis. These estimates describe the influence of the respective patient characteristics on ghrelin levels. The result of the linear mixed model analysis is the main result of the study. For n=85 patients, 169 observations of ghrelin levels were used for linear mixed model analysis (a baseline measurement for 1 patient was missing). A significant effect on ghrelin levels was found for response\*time interaction (F~1.81~=9.48; *P*=.0028) and gender (F~1.83~=4.69; *P*=.033). In this model, BMI (F~1.91~=0.22; *P*=.64), response (F~1.84~=0.14; *P*=.71), appetite (F~1.113~=0.95; *P*=.33), and time (equal to "treatment effect of LA"; F~1.83~=1.58; *P*=.21) did not show a significant effect on ghrelin levels. The main finding of the study (significant response\*time interaction) is demonstrated in [Figure 1](#F1){ref-type="fig"} by the crossed regression graphs. In this analysis, the estimated ghrelin levels do not differ significantly between responders and nonresponders at baseline and after LA (overlapping 95% CI). The estimated ghrelin levels at baseline were 4.51 ng/mL (95% CI: 2.61--6.41; *P*\<.0001) in nonresponders and 6.45 ng/mL (95% CI: 4.30--8.61; *P*\<.0001) in responders. The estimated ghrelin levels at endpoint were 6.53 ng/mL (95% CI: 4.65--8.41; *P*\<.0001) in nonresponders and 5.62 ng/mL (95% CI: 3.41--7.83; *P*\<.0001) in responders ([Figure 1](#F1){ref-type="fig"}.). The estimated ghrelin levels in men were 3.01 ng/mL lower compared with women (95% CI: -5.77 to 0.25; *P*=.033).

![Course of ghrelin levels in responders and nonresponders adjusted for gender and BMI: ghrelin increases in nonresponders and decreases slightly in responders to lithium augmentation. Ghrelin serum levels are presented as estimated means in ng/mL.](pyw08201){#F1}

Discussion {#s4}
==========

This is the first study investigating the course of ghrelin serum levels and the effect of treatment response on ghrelin levels during LA in patients with MDD. We found that during LA, ghrelin levels increase in nonresponders and slightly decrease in responders.

Our findings are in line with a study that found higher ghrelin serum levels in nonresponders with MDD to antidepressant treatment when compared with responders and normal controls ([@CIT0012]). These findings strengthen evidence that ghrelin might separate subgroups of depressive patients that respond to pharmacological treatment of depression. As depression-related stress continues in nonresponders but not (or less severely) in responders, our results are in line with studies reporting a stress-dependent increase in ghrelin levels ([@CIT0026]) and higher ghrelin serum levels in depressed individuals compared with healthy controls ([@CIT0009]).

The observed gender effect in our study is in line with previous studies reporting higher ghrelin levels in females than males in both healthy subjects ([@CIT0004]) and depressed patients ([@CIT0017]).

Our finding of an increase of ghrelin levels in nonresponders and a decrease in responders is in line with a preclinical study that reported an antidepressant-like effect following inhibition of ghrelin secretion after central or peripheral injection of ghrelin antisense DNA in rats ([@CIT0014]), suggesting a depressiogenic effect of ghrelin. A depressiogenic effect of ghrelin might theoretically be explained by the suppressive effect of ghrelin on serotonin release as well as its stimulatory action on HPA axis ([@CIT0016]). On the other hand, the majority of data, in particular from animal studies, revealed contrasting results (reviewed in [@CIT0029]; [@CIT0030]) and reported antidepressive and anxiolytic effects of ghrelin infusion ([@CIT0020]; [@CIT0005]), which might theoretically be explained by a stimulating effect of ghrelin on norepinephrine neurotransmission ([@CIT0007]) or via inhibition of glycogen-synthase-kinase 3 beta ([@CIT0031]). In this context, the ghrelin upregulation in nonresponders observed in our study could also be interpreted as an intrinsic or pharmacologically induced attempt to counteract depressive symptomatology. However, in a small sample, ghrelin infusion in patients with depression did not have a significant effect on depressive symptoms ([@CIT0018]). It is important to note that studies on the effect of ghrelin application have investigated short-term effects (15 minutes until a few days) after short-term application, whereas our study investigated long-term effects (4 weeks) after long-term application; thus, comparability of study results is limited.

Another explanation for the increase of ghrelin levels in nonresponders and the decrease in responders could be that we "only" observe secondary effects of depressive symptomatology and successful antidepressant treatment with LA: one of the main symptoms of MDD is reduced appetite and consecutively reduced food intake. Starvation is known to be a strong cue for ghrelin release, which could contribute to the observed ghrelin increase in nonresponders. Responders start to eat normally because of the relief of depressive symptomatology, which consecutively results in a decrease of ghrelin levels. Noteworthy, the result of our analysis is corrected for the effect of appetite on ghrelin levels, and we did not find a significant effect of response on BMI, which therefore does not support this hypothesis. Furthermore, other studies rather report lower ([@CIT0002]) or unchanged ([@CIT0017]) ghrelin serum levels in depressed subjects compared with healthy controls.

However, in our study, we did not find a correlation between severity of depression and ghrelin serum levels (data not shown). In summary, the course of ghrelin levels observed in our study could be interpreted in the context of either an antidepressive or a depressiogenic effect of ghrelin or rather reflect a secondary effect of depressive symptomatology, that is, reduced appetite and food intake.

Lithium has well-known neuroprotective effects ([@CIT0003]) and acts as a glycogen-synthase-kinase 3 beta inhibitor ([@CIT0013]). Interestingly, preclinical studies suggest that ghrelin can function as a neuroprotective agent that inhibits apoptotic pathways ([@CIT0031]) and that inactivation of GSK-3B contributes to the antiapoptotic effects of ghrelin. In the current analysis, we found ghrelin influenced by LA. In previously published analyses, we found that serum levels of brain-derived neurotrophic factor ([@CIT0025]) and fibroblast growth factor 23 ([@CIT0008]), both discussed in the context of neuroprotection, increased during LA. Therefore, one might speculate that ghrelin, brain-derived neurotrophic factor, and fibroblast growth factor 23 signalling are potentially involved in the neuroprotective action of lithium.

Previous studies investigating ghrelin levels during antidepressant treatment found an increase of serum ghrelin levels during treatment with maprotiline ([@CIT0023]) and amitriptyline ([@CIT0011]), while a decrease in ghrelin serum levels was reported during treatment with citalopram ([@CIT0002]) and mirtazapine ([@CIT0027]), electroconvulsive therapy ([@CIT0019]), or various antidepressive treatment strategies ([@CIT0022]). These heterogeneous findings could be due to different treatment strategies, small sample sizes, and different response rates. Limitations of these previous studies are small sample sizes and that ghrelin levels were not available together with longitudinally assessed clinical response data. The main strengths of our study are the relatively large sample size and the prospective study design. Our study extends existing data by providing (1) the first investigation of ghrelin serum levels during lithium treatment and (2) the first longitudinal investigation of the effect of treatment response on the course of ghrelin levels in patients with MDD.

Limitations of our study include the lack of a control group and a heterogeneous psychopharamcological comedication. We therefore cannot say if the observed changes in ghrelin levels are a lithium-specific effect. However, psychopharmacological comedication was stable during and before LA, and we did not find significant differences in this medication between responders and nonresponders, so that the influence of this confounding variable is limited. Also, we measured nonfasting ghrelin levels that were not taken after a standard meal and we did not obtain information on the time of the day when the blood samples were taken. Ghrelin levels strongly depend on food intake, appetite, and the anticipation of food, and its secretion has a circadian rhythm ([@CIT0015]) that increases variation of ghrelin levels. Nevertheless, we think that the large sample size could sufficiently compensate this confounder. Furthermore, we only have a pre- and postmeasurement of ghrelin levels, so we cannot distinguish between cause and effect (i.e., do ghrelin levels influence treatment response or does treatment response influence ghrelin levels?). To investigate this, a series of ghrelin and psychometric measurements with shorter time intervals is recommended for future studies.

In conclusion, the present results support the hypothesis that ghrelin serum concentrations might be involved in the response to pharmacological treatment of depression. Based on our data, one might speculate that an increase of the ghrelin serum concentration might be an indicator of nonresponse to LA in patients suffering from treatment-resistant depression. Further studies are needed to separate specific effects of different antidepressants on ghrelin concentration but also to address ghrelin downstream mechanisms.
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